Summit Master_rgb_png.png
Summit Therapeutics Selected for Emerging Science Presentation at the 2018 American Academy of Neurology Annual Meeting
March 28, 2018 07:00 ET | Summit Therapeutics plc
OXFORD, United Kingdom and CAMBRIDGE, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM) announces that it has been selected for an Emerging Science dual oral...
Summit Master_rgb_png.png
Summit Expands Enrolment in PhaseOut DMD Phase 2 Clinical Trial to Include Planned Additional Group
March 07, 2018 07:00 ET | Summit Therapeutics plc
Additional Group is Open to Patients Who Participated in Phase 1 Clinical Trials of EzutromidAllows Summit to Gather Additional Safety and Efficacy Data from a Broader Patient Population OXFORD,...
Summit Master_rgb_png.png
Ezutromid Significantly Reduced Muscle Damage in DMD Patients in 24-Week Interim Data From Summit’s PhaseOut DMD Clinical Trial
January 25, 2018 07:00 ET | Summit Therapeutics plc
Increase in Utrophin Protein Expression ObservedSummit Accelerating Preparations for Pivotal Clinical TrialEzutromid is a Potential Disease-Modifying Treatment for the Entire DMD Patient...
Summit Master_rgb_png.png
Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at 15th Action Duchenne International Conference
November 09, 2017 07:00 ET | Summit Therapeutics plc
New Preclinical Data Show Utrophin’s Positive Effect on Mitochondria Improving Muscle Health in DMD Model OXFORD, United Kingdom, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc...
Summit Master_rgb_png.png
Summit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular Dystrophy
September 25, 2017 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT)(AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Presents Data From Phase 1 Clinical Programme of Ezutromid at the European Paediatric Neurology Society Congress
June 22, 2017 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, June 22, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational Progress
June 14, 2017 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, June 14, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational Progress
March 29, 2017 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, March 29, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Therapeutics Recognises 10th Annual Rare Disease Day
February 28, 2017 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Master_rgb_png.png
Summit Therapeutics Reports Financial Results for the Third Quarter Ended 31 October 2016 and Operational Progress
December 15, 2016 07:00 ET | Summit Therapeutics PLC
OXFORD, United Kingdom, Dec. 15, 2016 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...